Comparative Pharmacology
Head-to-head clinical analysis: NORITATE versus PENTAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORITATE versus PENTAM.
NORITATE vs PENTAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole, after intracellular reduction, forms toxic intermediates that disrupt bacterial DNA and inhibit nucleic acid synthesis. It has anti-inflammatory and immunosuppressive properties in dermatological conditions.
Pentamidine is an antiprotozoal agent that interferes with nucleotide and nucleic acid synthesis, possibly by binding to DNA and inhibiting RNA and protein synthesis. It also affects membrane integrity and inhibits oxidative phosphorylation.
Topical application of a thin layer to affected area twice daily (morning and evening).
4 mg/kg intravenously once daily for 21 days (Pneumocystis jirovecii pneumonia); or 300 mg deep intramuscularly every 3 weeks for prophylaxis.
None Documented
None Documented
Clinical Note
moderatePentamidine + Gatifloxacin
"Pentamidine may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderatePentamidine + Rosoxacin
"Pentamidine may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderatePentamidine + Trovafloxacin
"Pentamidine may increase the hypoglycemic activities of Trovafloxacin."
Clinical Note
moderatePentamidine + Nalidixic acid
"Pentamidine may increase the hypoglycemic activities of Nalidixic acid."
Approximately 10 hours; may be prolonged in severe renal impairment.
Terminal elimination half-life: 6-24 hours (prolonged in renal impairment; up to 48 hours in anuria).
Primarily renal (approximately 90% as unchanged drug) and biliary/fecal (approximately 10%).
Renal: approximately 60-70% unchanged; biliary/fecal: minimal, <10%.
Category C
Category C
Antiprotozoal Agent
Antiprotozoal Agent